Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pleiotropic Effects of Finerenone on Organ-Specific Sympathetic Nerve Activity in Type 2 Diabetes with Diabetic Nephropathy
jRCTs041260018Recruiting
- Sponsor
- Bayer
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finerenone in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis, sponsored by Bayer. Primary endpoint: Muscle sympathetic nerve activity burst frequency at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs041260018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260018.